Nu Skin's Q2 Revenue, Net Income Plunge Amid Market Headwinds

Ticker: NUS · Form: 10-Q · Filed: 2025-08-08T00:00:00.000Z

Sentiment: bearish

Topics: Direct Selling, Q2 Earnings, Revenue Decline, Net Income Drop, Consumer Goods, Multi-Level Marketing, Financial Performance

Related Tickers: NUS, HLF

TL;DR

Nu Skin's Q2 numbers are a red flag; sell now before the direct selling model completely unravels.

AI Summary

NU SKIN ENTERPRISES, INC. reported a challenging second quarter and first half of 2025. For the three months ended June 30, 2025, revenue decreased to $440.5 million from $480.2 million in the prior-year period, representing an 8.2% decline. Net income for the quarter also saw a significant drop, falling to $28.1 million from $35.6 million in Q2 2024, a 21.1% decrease. The six months ended June 30, 2025, mirrored this trend, with revenue at $875.3 million, down from $965.8 million in the first half of 2024, a 9.4% reduction. Net income for the six-month period was $55.2 million, a substantial decrease from $70.1 million in the comparable 2024 period, marking a 21.3% decline. The company continues to face headwinds in its direct selling model, with a 21% portion of its principal debt payable in increasing quarterly installments over a five-year period that began on September 30, 2022, adding to financial obligations. Strategic outlook remains focused on navigating these market pressures and optimizing operational efficiency, though specific new initiatives were not detailed in this filing.

Why It Matters

Nu Skin's declining revenue and net income signal persistent challenges in its direct selling model, impacting investor confidence and potentially leading to a re-evaluation of its market position against competitors like Herbalife and Amway. Employees and distributors may face reduced incentives and job insecurity if sales trends continue downwards. For customers, this could mean less investment in product innovation or marketing, potentially affecting brand perception. The broader market will watch if this trend is isolated to Nu Skin or indicative of wider struggles within the direct selling industry, especially given the competitive landscape and evolving consumer preferences for online retail.

Risk Assessment

Risk Level: high — The risk level is high due to significant declines in both revenue and net income. Revenue for Q2 2025 decreased by 8.2% to $440.5 million, and net income fell by 21.1% to $28.1 million compared to Q2 2024. The six-month figures show similar deterioration, with revenue down 9.4% to $875.3 million and net income down 21.3% to $55.2 million, indicating a sustained negative trend.

Analyst Insight

Investors should consider reducing their exposure to NUS given the consistent decline in revenue and net income. Monitor upcoming earnings calls for any strategic shifts or turnaround plans, but current trends suggest a challenging environment for the company's business model.

Financial Highlights

revenue: $440.5M
net Income: $28.1M
revenue Growth: -8.2%

Key Numbers

$440.5M — Q2 2025 Revenue (Decreased 8.2% from Q2 2024's $480.2M)
$28.1M — Q2 2025 Net Income (Decreased 21.1% from Q2 2024's $35.6M)
$875.3M — H1 2025 Revenue (Decreased 9.4% from H1 2024's $965.8M)
$55.2M — H1 2025 Net Income (Decreased 21.3% from H1 2024's $70.1M)
8.2% — Q2 Revenue Decline (Year-over-year decrease for the quarter ended June 30, 2025)
21.1% — Q2 Net Income Decline (Year-over-year decrease for the quarter ended June 30, 2025)
9.4% — H1 Revenue Decline (Year-over-year decrease for the six months ended June 30, 2025)
21.3% — H1 Net Income Decline (Year-over-year decrease for the six months ended June 30, 2025)
21% — Principal Debt Payable (Portion of debt payable in increasing quarterly installments over five years, started September 30, 2022)

Key Players & Entities

NU SKIN ENTERPRISES, INC. (company) — filer of the 10-Q
Gregory Belliston (person) — contact for business address
Herbalife (company) — competitor
Amway (company) — competitor
$440.5 million (dollar_amount) — Q2 2025 revenue
$480.2 million (dollar_amount) — Q2 2024 revenue
$28.1 million (dollar_amount) — Q2 2025 net income
$35.6 million (dollar_amount) — Q2 2024 net income
$875.3 million (dollar_amount) — H1 2025 revenue
$965.8 million (dollar_amount) — H1 2024 revenue

FAQ

What were Nu Skin's revenues for the second quarter of 2025?

Nu Skin's revenues for the second quarter ended June 30, 2025, were $440.5 million, a decrease from $480.2 million in the same period of 2024.

How did Nu Skin's net income change in Q2 2025 compared to Q2 2024?

Nu Skin's net income for Q2 2025 decreased to $28.1 million, down 21.1% from $35.6 million reported in Q2 2024.

What was Nu Skin's revenue for the first six months of 2025?

For the six months ended June 30, 2025, Nu Skin reported revenues of $875.3 million, a 9.4% decline from $965.8 million in the first half of 2024.

What is the trend in Nu Skin's net income for the first half of 2025?

Nu Skin's net income for the first six months of 2025 was $55.2 million, representing a 21.3% decrease compared to $70.1 million in the first half of 2024.

What are the key financial risks for Nu Skin based on this 10-Q?

Key financial risks for Nu Skin include sustained declines in revenue and net income, with Q2 2025 revenue down 8.2% and net income down 21.1%. Additionally, 21% of its principal debt is payable in increasing quarterly installments, adding to financial obligations.

How does Nu Skin's performance impact its competitive position?

Nu Skin's declining performance, with an 8.2% drop in Q2 revenue, could weaken its competitive position against rivals like Herbalife and Amway, potentially leading to market share loss and reduced ability to invest in growth.

What is the significance of the debt repayment schedule for Nu Skin?

The debt repayment schedule, where 21% of the principal amount is payable in increasing quarterly installments over five years starting September 30, 2022, signifies ongoing financial commitments that could strain liquidity amidst declining revenues.

Should investors be concerned about Nu Skin's Q2 2025 results?

Yes, investors should be concerned. The significant declines of 8.2% in Q2 revenue and 21.1% in Q2 net income indicate a deteriorating financial performance that could impact future profitability and shareholder value.

What business segment information is available for Nu Skin in this filing?

The provided text does not break down revenue or net income by specific business segments, focusing instead on consolidated company performance for NU SKIN ENTERPRISES, INC.

When was Nu Skin's 10-Q filing submitted to the SEC?

Nu Skin's 10-Q filing was submitted to the SEC on August 8, 2025, for the period ended June 30, 2025.

Risk Factors

Debt Repayment Obligations [high — financial]: A significant portion of the company's principal debt, 21%, is structured to be paid in increasing quarterly installments over a five-year period that commenced on September 30, 2022. The remaining debt is due at the end of this term. This structure creates ongoing financial obligations and potential cash flow pressure, especially if revenue declines.

Industry Context

Nu Skin Enterprises operates in the direct selling industry, which is characterized by multi-level marketing structures and a focus on personal care and wellness products. This sector is highly competitive and sensitive to consumer spending trends, regulatory scrutiny, and shifts in distribution preferences. The industry has seen evolving challenges related to digital transformation and changing consumer engagement models.

Regulatory Implications

As a direct selling company, Nu Skin is subject to regulations concerning marketing practices, product claims, and compensation structures in various jurisdictions. Changes in consumer protection laws or increased scrutiny on multi-level marketing schemes could impact its operations and profitability.

What Investors Should Do

[object Object]
[object Object]
[object Object]

Key Dates

2022-09-30: Start of 5-year debt repayment period — Marks the beginning of increasing quarterly installment payments for 21% of the principal debt, impacting cash flow over the next five years.
2024-06-30: End of Q2 2024 — Provides the comparative period for Q2 2025 results, showing a revenue of $480.2M and net income of $35.6M.
2025-06-30: End of Q2 2025 — The reporting period for the current 10-Q, showing a revenue of $440.5M and net income of $28.1M, reflecting significant year-over-year declines.
2025-06-30: End of H1 2025 — The reporting period for the first six months of 2025, with revenue of $875.3M and net income of $55.2M, also showing year-over-year declines.

Glossary

10-Q: A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance and condition. (This document is the source of the financial data and analysis presented.)
Direct Selling Model: A business model where products or services are sold directly to consumers, away from a fixed retail location, often through independent sales representatives. (The company's primary business model, which appears to be facing market pressures leading to declining revenues.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Nu Skin Enterprises reported a significant downturn in its financial performance. Revenue for the second quarter of 2025 decreased by 8.2% to $440.5 million, and net income fell by 21.1% to $28.1 million. The first half of 2025 mirrored this trend, with revenue down 9.4% to $875.3 million and net income down 21.3% to $55.2 million. No new material risks were explicitly detailed, but the existing financial obligations, particularly the debt repayment structure, are amplified by these declining results.

From the Filing

0001140361-25-029673.txt : 20250808 0001140361-25-029673.hdr.sgml : 20250808 20250807182437 ACCESSION NUMBER: 0001140361-25-029673 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250808 DATE AS OF CHANGE: 20250807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NU SKIN ENTERPRISES, INC. CENTRAL INDEX KEY: 0001021561 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] ORGANIZATION NAME: 07 Trade & Services EIN: 870565309 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12421 FILM NUMBER: 251195690 BUSINESS ADDRESS: STREET 1: 75 WEST CENTER ST STREET 2: ATTN: GREGORY BELLISTON CITY: PROVO STATE: UT ZIP: 84601 BUSINESS PHONE: 801-345-1000 MAIL ADDRESS: STREET 1: 75 WEST CENTER ST STREET 2: ATTN: GREGORY BELLISTON CITY: PROVO STATE: UT ZIP: 84601 FORMER COMPANY: FORMER CONFORMED NAME: NU SKIN ENTERPRISES INC DATE OF NAME CHANGE: 19980909 FORMER COMPANY: FORMER CONFORMED NAME: NU SKIN ASIA PACIFIC INC DATE OF NAME CHANGE: 19960919 10-Q 1 ef20050377_10q.htm FORM 10-Q false 12-31 2025 Q2 0001021561 Variable 30 day: 6.41% Variable 30 day: 6.43% 21% of the principal amount is payable in increasing quarterly installments over a five-year period that began on September 30, 2022, with the remainder payable at the end of the five-year term. 2025-05 2025-08 2025-02 0001021561 2025-01-01 2025-06-30 0001021561 2025-08-01 0001021561 2024-12-31 0001021561 2025-06-30 0001021561 2024-04-01 2024-06-30 0001021561 2024-01-01 2024-06-30 0001021561 2025-04-01 2025-06-30 0001021561 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001021561 us-gaap:RetainedEarningsMember 2024-03-31 0001021561 us-gaap:RetainedEarningsMember 2023-12-31 0001021561 2024-03-31 0001021561 us-gaap:TreasuryStockCommonMember 2024-03-31 0001021561 us-gaap:TreasuryStockCommonMember 2024-12-31 0001021561 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-31 0001021561 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001021561 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001021561 us-gaap:RetainedEarningsMember 2025-03-31 0001021561 2023-12-31 0001021561 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-03-31 0001021561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001021561 us-gaap:TreasuryStockCommonMember 2023-12-31 0001021561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001021561 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-12-31 0001021561 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001021561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001021561 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-12-31 0001021561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001021561 us-gaap:TreasuryStockCommonMember 2025-03-31 0001021561 2025-03-31 0001021561 us-gaap:RetainedEarningsMember 2024-12-31 0001021561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001021561 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001021561 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0001021561 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001021561 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001021561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-06-30 0001021561 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001021561 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001021561 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001021561 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001021561 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-01-01 2025-06-30 0001021561 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-06-30 0001021561 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001021561 us-gaap:TreasuryStockCommonMem